Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Abstract

IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.